Novartis Ag (NVSEF) — SC 13D/A Filings

SC 13D/A Filings (6)

• Novartis AG Files SC 13D/A Amendment for MorphoSys AG — Oct 17, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco Germany AG, has filed an amendment (Amendment No. 6) to its Schedule 13D regarding MorphoSys AG. The filing,
• Novartis AG Files SC 13D/A Amendment for MorphoSys AG — Aug 15, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco Germany AG, has filed an amendment (Amendment No. 5) to its Schedule 13D concerning MorphoSys AG. The filing,
• Novartis AG Amends MorphoSys AG Filing — Jun 21, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco Germany AG, has amended its Schedule 13D filing concerning MorphoSys AG. The amendment, filed on June 21, 202
• Novartis AG Amends Schedule 13D for MorphoSys AG — Jun 17, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco AG, has filed an amendment (no. 3) to its Schedule 13D concerning MorphoSys AG. This filing, dated June 17, 2
• Novartis Amends MorphoSys Acquisition Filing — Jun 10, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco AG, filed an amendment (No. 2) to its Schedule 13D on June 10, 2024, regarding its acquisition of MorphoSys A
• Novartis AG Amends MorphoSys AG Filing — May 28, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco AG, has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of MorphoSys

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX